349 related articles for article (PubMed ID: 23628493)
1. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.
Umbehr MH; Müntener M; Hany T; Sulser T; Bachmann LM
Eur Urol; 2013 Jul; 64(1):106-17. PubMed ID: 23628493
[TBL] [Abstract][Full Text] [Related]
2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
3. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
4. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M
Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037
[TBL] [Abstract][Full Text] [Related]
5. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
Evangelista L; Zattoni F; Guttilla A; Saladini G; Zattoni F; Colletti PM; Rubello D
Clin Nucl Med; 2013 May; 38(5):305-14. PubMed ID: 23486334
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.
Evangelista L; Guttilla A; Zattoni F; Muzzio PC; Zattoni F
Eur Urol; 2013 Jun; 63(6):1040-8. PubMed ID: 23036576
[TBL] [Abstract][Full Text] [Related]
9. State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer.
Vagnoni V; Brunocilla E; Bianchi L; Porreca A; Borghesi M; Pultrone CV; Angelo P; Chessa F; Ceci F; Mengoni F; Dababneh H; Castellucci P; Fanti S; Martorana G; Schiavina R
Arch Esp Urol; 2015 Apr; 68(3):354-70. PubMed ID: 25948806
[TBL] [Abstract][Full Text] [Related]
10. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
11. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
13. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
[TBL] [Abstract][Full Text] [Related]
15. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Incerti E; Mapelli P; Kirienko M; Briganti A; Gandaglia G; Montorsi F; Gianolli L; Picchio M
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):877-84. PubMed ID: 25697127
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.
Guo Y; Wang L; Hu J; Feng D; Xu L
PLoS One; 2018; 13(9):e0203400. PubMed ID: 30192819
[TBL] [Abstract][Full Text] [Related]
17. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
[TBL] [Abstract][Full Text] [Related]
18. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline.
Giovacchini G; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):354-66. PubMed ID: 23013665
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
20. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]